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BACKGROUND AND IMPORTANCE
Deep venous thrombosis (DVT) and its sequelae
are important medical problems that affect 260,000
to 600,000 persons in the United States each year.1,2
Patients with DVT frequently have a postthrombot-
ic syndrome characterized by pain, edema, hyperpig-
mentation, stasis ulceration, and other symptoms of
venous valvular insufficiency.3-6
The relation between venous thrombosis and
development of valve dysfunction is not well under-
stood. Not all patients with DVT have valvular insuf-
ficiency, suggesting that the causation is multifacto-
rial. Virchow’s triad of stasis, injury, and hypercoag-
ulability is classically associated with development of
DVT. In addition, vein segments that have marked
outflow obstruction are more commonly associated
with DVT than normally patent veins. Over time,
DVT reorganizes and usually recanalizes. 
Duplex studies of recanalized segments reveal a
thickened venous wall in addition to areas of residual
fibrinous thrombus.7-9 Proliferative vein wall changes
are believed to arise from the process of thrombus
organization, which appears to be acutely initiated by
inflammatory cell infiltration10 but chronically
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Purpose: An in vivo model of acute deep venous thrombosis was developed in rats to
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appears to consist of smooth muscle–type fibrocellu-
lar proliferation.11,12 In experimental thrombosis of
pig jugular veins, Sigel et al.13 likened thrombus
organization to the development of intimal hyperpla-
sia. Vein wall proliferative thickening with resultant
loss of compliance may be severe enough to impair
valve leaflet coaptation and result in reflux, progres-
sive fibrosis, and permanent dysfunction of valves.
We suspect that thrombus contains biologically
active factors that stimulate cellular and structural
alterations and lead to postthrombotic venous
abnormalities. If this is true, prolonged exposure to
thrombus may result in development of more severe
pathologic conditions. We hypothesized that venous
outflow obstruction impairs recanalization and
results in prolonged exposure of vein walls to throm-
bus. This prolonged thrombus exposure would
allow biologically active factors within the thrombus
to stimulate local pathologic changes in the venous
wall. We describe the role of venous thrombosis,
outflow obstruction, and recanalization over time in
the development of secondary vein wall changes in
an in vivo rat model of acute DVT.
METHODS
All rats were treated in accordance with the
Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources,
Commission of Life Sciences, National Research
Council, Washington: National Academy Press;
1996). Institutional review and approval was
obtained from the division of laboratory animal care
at Stanford University (protocol 4866).
Male Sprague-Dawley rats weighing 300 to 500
gm were placed under general pentobarbital anesthe-
sia (Nembutal, 50 mg/kg intraperitoneally). Femoral
vein thrombosis was performed as follows. The left
femoral vein was isolated by means of careful dissec-
tion and cautery of branch points with a no-touch
technique. Thrombosis was achieved by means of
proximal ligation with a 4-0 silk ligature or temporary
24-hour occlusion with an atraumatic 8 mm
microvascular clip (Roboz, Rockville, Md.). As con-
trols, right femoral veins were similarly isolated but
not ligated or clamped. Adequate thrombus forma-
tion was confirmed visually and through lack of flow
as detected with a directional Doppler flow cuff (CBI-
8000; Crystal Biotech, Hopkinton, Mass.). Doppler
flow was recorded as an analog waveform on a screen
with a grid. The flow probe was oriented such that
flow toward the head was positive, flow toward the
tail was negative, and thrombosed veins showed no
flow. Venous flow was assessed in control and experi-
mental femoral veins under pentobarbital anesthesia
before ligation or clipping, after ligation or clipping,
after clip removal, and before euthanasia. At intervals
over 5 weeks, rats were killed with an overdose of bar-
biturates, and their veins were harvested, embedded
in OCT compound (Tissue Tek; Miles Scientific,
Elkhart, Ind.) and snap frozen in liquid nitrogen.
Seven micron frozen sections were obtained by
means of slicing vein segments at –18° C in a cryo-
static microtome (Microm HM505E; Fisher
Scientific, Santa Clara, Calif.). Histologic evaluation
was accomplished by means of staining with hema-
toxylin and eosin, Movat’s elastin stain, Masson’s
trichrome (American Histolabs, Gaithersburg, Md.),
and Ladd’s multistain (Ladd Research, Burlington,
Vt.). Immunohistochemistry was performed with
biotin-avidin conjugated detection (Vectastain ABC,
Burlingame, Calif.) of anti-muscle actin mouse mon-
oclonal antibody HHF35 (Enzo Diagnostics,
Farmingdale, N.Y.).
Wall thickness was determined by means of
counting cells on representative sections through
the midvein area (4 to 6 mm distal to the ligature or
clamping site) under a light microscope with 400·
magnification. A single reader blinded to the source
and time course of each specimen performed cell
counts in triplicate. Values for each specimen were
reported as mean value of the triplicate readings.
Thrombi were indirectly quantitated by means of
an iodine 125 radiolabeled fibrinogen assay. Purified
human fibrinogen (Alexis Corporation, San Diego,
Calif.) was labeled by means of incubation of 100 m g
with 0.5 to 1 mCi of 125I (Dupont NEN, Boston,
Mass.) and one Iodobead bead (Pierce, Rockford,
Ill.) in phosphate buffered saline solution for 5 to 10
minutes at room temperature. Labeled protein was
separated from unincorporated radioactivity by
means of passage through a G25 Sephadex column
(Sigma, St. Louis, Mo.). Elution peaks with activities
greater than 105 counts per minute per microliter
were used for the assay. Just before femoral vein
thrombosis, rats were subjected to laparotomy and
injection of 125I fibrinogen representing approxi-
mately 2 · 106 counts directly into the vena cava.
The labeled fibrinogen was allowed to circulate and
equilibrate over 20 minutes before thrombosis was
performed as described earlier. When the rats were
killed, veins were harvested, rinsed in saline solution,
and counted in a gamma counter. Caval blood (100
m l) was withdrawn and sent for gamma counting and
determination of total fibrinogen content. Specific
activity of fibrinogen in the caval blood was used as
a standard in quantifying femoral venous thrombi.
Three additional rats were used to evaluate lung
radioactivity for evidence of pulmonary emboliza-
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tion. One rat was subjected to both femoral veins
without ligation or clipping after vena caval injection
of radiolabeled fibrinogen. A second rat was subject-
ed to clipping of the right femoral vein and ligation
of the left femoral vein after vena caval injection of
radiolabeled fibrinogen. A third rat was subjected to
ligation of the right femoral vein and clipping of the
left femoral vein after vena caval injection of radiola-
beled fibrinogen. The femoral clips were removed
from rats 2 and 3 on day 1. On day 7, both lungs
from all three rats were excised after pentobarbital
euthanasia, rinsed in normal saline solution, counted
in a gamma counter, and compared with a standard
of 100 m l of vena caval blood.
Data of all specimens in each time point are
reported as mean value ± SD. Statistically significant
differences for all data points were determined with
paired t-test analysis (Statview; Abacus Concepts,
Berkeley, Calif.). A p value less than 0.05 was con-
sidered significant.
RESULTS
Thirty-eight rats were subjected to left femoral
vein thrombosis with production of long-term out-
flow obstruction by means of placement of a proxi-
mal ligature (group A). Twenty rats were subjected
to thrombosis by means of temporary 24-hour
occlusion with a microvascular clamp (group B). A
parallel series of 36 rats were subjected to thrombo-
sis after I125 fibrinogen labeling to quantitate throm-
bus formation and resolution over time. Thrombus
formation was successfully realized in the test veins
of all experimental animals. No thrombus formed in
any of the control veins, which also showed no evi-
dence of cellular or structural changes.
Veins in group A had marked neointimal and
medial cellular proliferation beginning 4 days after 
ligation and peaking 7 to 14 days after ligation (27 ±
7 vs 6 ± 2 cells, p < 0.01; Table I). Immuno-
histochemical staining of sections at days 7 and 10
confirmed that the neointimal and medial cellular pro-
liferation consisted mainly of smooth muscle–type
cells. Within 3 weeks, veins from group A were found
to have spontaneously recanalized with resumption of
normal cephalad flow. The proximal ligature remained
intact, yet the obstruction was bypassed through
development of neovascular channels (Fig. 1). With
resumption of cephalad flow, the neointimal prolifera-
tion subsided, but the medial cellular growth persisted,
resulting in chronic thickening of the postthrombotic
veins (11 ± 3 vs 5 ± 1 cells, p < 0.01; Fig. 2). In con-
trast, group B veins had significantly less wall thicken-
ing (13 ± 2 vs 5 ± 1 cells, p < 0.01, peak at 4 days;
Table II) and did not induce growth of local collater-
al vessels. The cellular proliferations in both groups
had similar histologic features (Fig. 3), but the
chronicity and degree of proliferation were significant-
ly different (Fig. 4). By the second week, group B
veins regained normal appearance and resumed nor-
mal cephalad flow.
Thrombus quantitation is summarized in Table
III and Fig. 5. Early thrombus extension was seen in
group A (day 4) and was followed by resolution
within 2 weeks. In contrast, no thrombus extension
was seen in group B veins. These thrombi rapidly
lysed within 1 week. No evidence of pulmonary
embolization was seen at 1 week (Table IV).
DISCUSSION
This work demonstrated an important temporal
relation between exposure of thrombus to the
venous wall and venous wall remodeling with neoin-
timal and myocellular proliferation. Our results sug-
gested that the longer thrombus is exposed to the
vein wall, the more vigorous and sustained are the
vascular remodeling and subsequent wall thickening.
Although this evidence is indirect, the differences in
venous wall morphologic features between chronic
outflow obstruction with longer thrombus exposure
and temporary outflow obstruction with shorter
thrombus exposure in this model are important.
This difference is even more interesting because
chronic outflow obstruction induced local neovascu-
lar channel formation, whereas temporary outflow
obstruction did not.
There may be important differences between the
procoagulant factors at work in this rat model and the
human condition of DVT. However, there are impor-
tant similarities between the key components of the
coagulation cascade in both human and rat systems
and important homologies between the coagulation
proteins in both species.14,15 These similarities suggest
that this model might provide valuable insight into the
pathogenesis of venous thrombotic disease.
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Table I. Wall thickness of group A veins
Day n (38) Intima Media Total Control
1 4 2 ± 1 4 ± 1 6 ± 1 5 ± 1
4 4 7 ± 4 6 ± 2* 13 ± 5* 6 ± 1
7 6 16 ± 4* 11 ± 3* 27 ± 6* 6 ± 1
10 6 15 ± 3* 12 ± 5* 27 ± 7* 6 ± 2
14 6 15 ± 6* 8 ± 3* 23 ± 7* 5 ± 1
21 4 6 ± 3 5 ± 1* 11 ± 3* 5 ± 1
28 4 3 ± 1 7 ± 2* 10 ± 2* 5 ± 1 
35 4 2 ± 1 8 ± 2* 10 ± 2* 5 ± 1
Values are mean number of cells ± SD.
*p < 0.05 compared with control.
The response of the vein wall to venous throm-
bosis has been poorly characterized to date.
Historical evaluation of pathologic specimens from
patients with postthrombotic venous insufficiency
identified a fibrotic thickening of the involved
venous segments.11 Fibrous intimal thickening was
commonly found in the deep veins of the thighs of
the mostly elderly patients in that autopsy series. The
time course between acute DVT and the pathologic
examination was not accurately recorded, and most
of the patients with DVT had not had clinical symp-
toms. Small fibrous strings, ridges, and thickenings
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Fig. 1. A, Gross view of day 0 femoral vein ligation after skeletonization. No collateral
branches are present around the area of ligation (lig) (original magnification, 25· ). IEL, inter-
nal elastic lamina. B, Gross view of 28-day ligature-thrombosed (group A) vein that has grown
several local neovascular channels (NVC) around the ligature (original magnification, 25· ). C,
Sagittal section through the same vein showing a large NVC and tightly bound silk ligature
(original magnification, 25· ; Ladd’s Multistain). D, Close-up view of the NVC and ligature in
B. The ligature is still tightly bound around the two original vein walls (original magnification,
400· ; Ladd’s Multistain).
Table II. Wall thickness of group B veins
Day n (20) Intima Media Total Control
1 2 2 ± 1 3 ± 1 5 ± 1 5 ± 1
4 4 8 ± 2* 5 ± 2 13 ± 2* 5 ± 1
7 4 4 ± 2 7 ± 2* 11 ± 2* 4 ± 1
10 4 3 ± 1 6 ± 2* 9 ± 2 6 ± 1 
14 4 2 ± 1 4 ± 1 6 ± 1 6 ± 1
21 2 2 ± 1 4 ± 1 6 ± 1 5 ± 1
Values are mean number of cells ± SD.
*p < 0.05 compared with control.
Table III. Thrombus quantitation
Day Group A Group B Control
1 1.97 ± 0.18* 1.76 ± 0.01* 0.16 ± 0.05
4 8.54 ± 1.98* 1.09 ± 0.79 0.14 ± 0.05
7 0.76 ± 0.41 0.34 ± 0.18 0.18 ± 0.10
10 2.86 ± 2.67 0.32 ± 0.04 0.15 ± 0.07
14 1.25 ± 0.12 0.94 ± 0.87 Not assayed
Thrombosis occurred in 36 rats to give n = 4 veins per time point
for groups A and B; n = 8 per time point for controls. Day 14 rats
(total = 4) underwent clamping or ligation of left and right
femoral veins in alternate manner without controls. No significant
difference was found between right and left veins within each
group. All values in milligrams of fibrinogen incorporated into
thrombus ± SD.
*p < 0.05 compared with control.
of the intima, visible to the naked eye, were found in
most patients, whereas extensive, coarse, trabeculat-
ed intimal thickening and sclerosed lumenless veins
were less frequently encountered. 
In the living state, most of our knowledge of
DVT resolution has come from duplex ultrasound
examinations, mostly of patients with symptoms and
therefore of patients who generally have been treat-
ed with systemic anticoagulation, thrombolysis, or
both. True natural history data on the resolution of
DVT and its effects on the venous wall are lacking.
Venous duplex studies prospectively assessing the
evolution of DVT have shown 50% to 70% of limbs
with venous thrombosis have valvular incompetence
6 to 9 months after the acute episode of DVT,7,8
with thickening of the previously thrombosed but
subsequently recanalized venous wall. Other studies
have identified duplex findings after recanalization
of DVT that suggest future development of post-
thrombotic venous insufficiency.9 The changes sug-
gestive of chronic damage included thickening of
the venous wall, reflux, and abnormal valves. A vein
wall was considered thickened when it was twice the
thickness of a normal venous segment, with
increased echogenicity of the damaged venous wall
brighter than the normal vessel wall. These findings
were identified among 44% of patients whose DVT
resolved by 6 months of follow-up study.9 Other
studies have shown totally occluded veins more
commonly have reflux than do veins with only par-
tial obstruction.8 Complete obstruction in our
model led to more severe morphologic changes in
the venous wall after DVT. 
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Fig. 2. Photomicrographs show ligature-thrombosed (group A) vein walls. A, Control vein.
Note scant cellularity, single-layer intima, and thin media. B, Seven-day thrombosed vein. Note
marked intimal and medial proliferation separated by the internal elastic lamina (IEL). C, A 28-
day-old thrombosis. Note regression of intimal proliferation with marked fibrosis of the inti-
ma and persistently thickened and fibrocellular media (original magnification, 400· ; Movat’s
elastin and collagen stain).
Table IV. Rat lung radioactivity after thrombosis
Venous CPM
Fibrinogen (mg)
Animal treatment (lung/100 m l) Lung Right leg Left leg
1 Control right 9.54* 2.9 0 0.14
Control left
2 Clip right 11.86* 3.4 0.29 3.1
Ligate left
3 Ligate right 9.95* 3.0 9.5 2.7
Clip left
CPM, counts per minute.
*p = not significant.
It is apparent that thrombus propagation is
common in acute DVT. In plasma, the bulk of
thrombin generation takes place after a thrombus
has formed, and thrombin is bound to fibrin and
fibrinogen within the developing thrombus.16 This
fibrin-bound thrombin remains biologically and
functionally active within the clot and as thrombol-
ysis ensues and plasmin degrades the thrombus.17
This clot-bound thrombin is protected from inhi-
bition by heparin-antithrombin III but is suscepti-
ble to newer antithrombin III–independent direct
thrombin inhibitors such as hirudin and hirulogs.18
Our model showed thrombus extension both visu-
ally with the vessel wall dilating and with the radi-
olabeled fibrinogen assay over the first 4 days after
acute thrombosis in the outflow obstruction
group. The temporary outflow obstruction group,
however, did not show thrombus extension. The
thrombosed femoral vein enlarged initially during
development of acute thrombosis in both groups,
but the DVT of the group with temporary obstruc-
tion resolved rapidly after relief of outflow obstruc-
tion. No increased radiolabeled fibrinogen was
detected in the lungs of either group, so thrombus
resolution was a result of thrombolysis and not of
embolization.
As thrombolysis progressed, active thrombin was
released locally in both groups. In the obstructed
group, the thrombin might continue to act locally,
either generating new fibrin and extending the
thrombus or stimulating its unique receptor
expressed on the venous wall and on many of the
cells of the local inflammatory cell infiltrate. In the
group with temporary obstruction, the active
thrombin would be progressively cleared and inacti-
vated by antithrombin III remote from the injury
site, with minimal chance for interaction of the
thrombin locally with its receptor.
The thrombin receptor is a G-protein coupled
receptor, a member of the heptahelical transmem-
brane family of receptors that includes adrenergic,
cholinergic, and serotoninergic receptors, which is
highly conserved among rat and human tissues.19,20
The thrombin receptor was initially identified in an
immortalized megakaryocyte cell line but subse-
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Fig. 4. Comparison of wall thickness between groups A
and B. Wall thickness peaks earlier and at a lower level in
unobstructed group B veins. There is persistent chronic
wall thickening of group A veins even after resumption of
normal flow.
Fig. 5. Comparison of thrombus quantity between
groups A and B. There is extension of thrombus in group
A veins up to 4 days after the initial thrombosis.
Fig. 3. Photomicrograph shows sections through a 7-day
thrombosed group A vein on the (A) and a 4-day throm-
bosed group B vein (B). Note similar intimal and medial
cellularity in both specimens (original magnification,
400· ; hematoxylin and eosin and Ladd’s Multistain). IEL,
internal elastic lamina.
quently has been determined to be the platelet
receptor for thrombin responsible for release of pre-
formed protein factors, including platelet derived
growth factor.19,20 Activation of the thrombin
receptor by thrombin involves a novel proteolytic
mechanism of receptor activation.19-21 Thrombin
has long been known to stimulate many cellular
responses that are distinct from its actions on the
coagulation cascade. Thrombin has potent chemo-
tactic activities for monocytes,22 is mitogenic for sev-
eral cell types, including vascular smooth muscle
cells, fibroblasts and mesenchymal cells,23,24 and
stimulates vascular contraction in the absence of
endothelium and vascular relaxation in the presence
of endothelium.25 Many if not all of these cellular
responses are mediated by the thrombin receptor.
Thrombin stimulates proliferation of vascular
smooth muscle cells, and the proteolytically activat-
ed thrombin receptor is the mediator.26 Small pep-
tides mimicking the amino terminus of the activated
thrombin receptor (TRAP proteins) have been
shown to mimic the effects of thrombin in the pro-
motion of cellular events such as secretion and mito-
genesis in the presence of the receptor but without
active thrombin.27 These TRAP proteins may pro-
vide a tool to more clearly define the role of throm-
bin in vascular wall remodeling. 
Multiple experimental models and pathologic
examinations of DVT have been described, and sev-
eral authors have documented that organization and
recanalization of venous thrombi proceed at a con-
stant yet variable rate.11,28-30 The organization of
thrombus has been extensively studied in the acute
phase and appears to depend initially on circulating
inflammatory cells recruited by generation of local
cytokines.10 Leukocyte infiltration, both mononu-
clear and polymorphonuclear, initiates a plasmin-
independent fibrinolysis through enzymes such as
cathepsin G and elastase.31,32 Continued resolution
of the thrombus then involves both tissue-type plas-
minogen activator (tPA) and urokinase type plas-
minogen activator (uPA) involved in local genera-
tion of plasmin within the thrombus. It appears that
both plasminogen activators are delivered to the
thrombus by monocytes intercalated in the throm-
bus.12 Local and adjacent endothelial expression of
tPA did not appear to be significantly involved in
thrombus resolution.
Longer follow-up study of the resolution of
venous thrombosis in a pig model of jugular venous
thrombosis identified a process similar to intimal
hyperplasia as the primary method of thrombus
organization.13 These findings were not dissimilar to
the histologic findings in our study. The investiga-
tors of the pig model of thrombosis concluded that
the electrical injury used to initiate thrombosis was
the stimulus for development of the intimal hyper-
plasia observed. In our model, no similar intimal
injury was applied, but the thrombotic and throm-
bolytic processes were serially observed through
similar time points, and the neointimal proliferation
described by Sigel et al.13 was similar to our own
findings.
The most unexpected but perhaps most stimu-
lating finding of this study was the neovascular chan-
nels that developed in the chronic occlusion group.
Angiogenesis continues to be an area of active inves-
tigation, predominantly in the field of oncology.33
Several growth factors are identified as critical in the
progression of angiogenesis. They include acidic
fibroblastic growth factor, basic fibroblastic growth
factor, tumor necrosis factor- a , and vascular
endothelial growth factor.34,35 Plasminogen activa-
tors, predominantly uPA associated with a cell-
bound receptor are also important mediators of
angiogenesis.36 Thrombin has been identified as a
promoter of angiogenesis, a process requiring acti-
vation of the membrane-bound thrombin recep-
tor.37 In our group A with chronic outflow obstruc-
tion, local thrombin release and stimulation of mem-
brane-bound receptor associated with local uPA
activity may explain the initiation of angiogenesis
and ultimately the neovascular channels visualized.
In our group B, the outflow obstruction was tem-
porary, and therefore local accumulation of active
thrombin and uPA decreased and neovascular chan-
nels were not initiated. Perhaps some form of neo-
vascularization may explain the recurrent symptoms
that develop after high ligation without stripping for
greater saphenous vein incompetence.
In conclusion, we described a model of venous
thrombosis in the rats that was used to evaluate
acute and chronic morphologic changes in the
venous wall during thrombosis and recanalization.
In rats with temporary outflow obstruction, DVT
resulted in rapid thrombolysis and transient venous
wall proliferative changes. The addition of chronic
venous outflow obstruction led to early extension of
venous thrombosis, development of a sustained
proliferative neointimal cellular process, and devel-
opment of neovascular channels to bypass the
chronic outflow obstruction. Thrombin, a pluripo-
tent protease, may mediate many of these processes
through its unique receptor. We are currently 
evaluating the role of the thrombin receptor in 
this model.
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 1 See-Tho and Harris 121
REFERENCES
1. Carter CJ. The natural history and epidemiology of venous
thrombosis. Prog Cardiovasc Dis 1994;36:423-38.
2. Weinman EE, Salzman EW. Deep vein thrombosis. N Engl J
Med 1994;331:1630-41.
3. Alpert JS, Dalen JE. Epidemiology and natural history of
venous thromboembolism. Prog Cardiovasc Dis
1994;36:417-22.
4. Carter CJ. The pathophysiology of venous thrombosis. Prog
Cardiovasc Dis 1994;36:439-46.
5. Halliday P. Development of the post-thrombotic syndrome:
its management at different stages. World J Surg
1990;14:703-10.
6. Strandness DE, Langlois Y, Cramer M, et al. Long term
sequelae of acute venous thrombi: rate and outcome. JAMA
1983;250:1289-95.
7. Ramhorst B, Bemmelen PS, Hoenveld H, et al. Thrombus
regression of spontaneous thrombolysis with duplex scan-
ning. Circulation 1992;86:414-9.
8. Markel A, Manzo RA, Bergein RO, Strandness DE. Valvular
reflux after deep vein thrombosis: incidence and time of
occurrence. J Vasc Surg 1992;15:377-84.
9. Caprini JA, Arcelus JI, Hoffman KN, et al. Venous duplex
imaging follow-up of acute symptomatic deep vein thrombo-
sis of the leg. J Vasc Surg 1995;21:472-6.
10. Wakefield TW, Strietert RM, Prince MR, et al. Pathogenesis
of venous thrombosis: a new insight. Cardiovasc Surg
1997;5:6-15.
11. Sevitt S. The mechanism of canalization in deep vein throm-
bosis. J Pathol 1973;110:153-65.
12. Northeast ADR, Soo KS, Bobrow LG, et al. The tissue plas-
minogen activator and urokinase response in vivo during nat-
ural resolution of venous thrombus. J Vasc Surg 1995;
22:573-9.
13. Sigel B, Swami V, Can A, et al. Intimal hyperplasia producing
thrombus organization in an experimental venous thrombo-
sis model. J Vasc Surg 1994;19:350-60. 
14. Solis MM, Vitti M, Cook J, et al. Recombinant soluble
human thrombomodulin: a randomized, blinded assessment
of prevention of venous thrombosis and effects on hemosta-
tic parameters in a rat model. Thromb Res 1994;73:385-94.
15. Stanton C, Ross RP, Hutson S, Wallin R. Processing and
expression of rat and human clotting factor–X-encoding
cDNAs. Gene 1996;169:269-73.
16. Kumar R, Beguin S, Hemker HC. The influence of fibrino-
gen and fibrin on thrombin generation: evidence for feedback
activation of the clotting system by clot bound thrombin.
Thromb Haemost 1994;72:713-21.
17. Francis CW, Markham RE Jr, Barlow GH, et al. Thrombin
activity of fibrin thrombi and soluble plasmic derivatives. J
Lab Clin Med 1983;102:220-30.
18. Weitz JI, Hudoba M, Massel D, et al. Clot bound thrombin
is protected from inhibition by heparin-antithrombin III and
is susceptible to inactivation by antithrombin III-indepen-
dent inhibitors. J Clin Invest 1990;86:385-91.
19. Vu THK, Hung DT, Wheaton VI, Coughlin SR. Molecular
cloning of a functional thrombin receptor reveals a novel pro-
teolytic mechanism of receptor activation. Cell 1991;
64:1057-68.
20. Zhong C, Hayzer DJ, Corson MA, Runge MS. Molecular
cloning of the rat vascular smooth muscle thrombin receptor.
J Biol Chem 1992;267:16975-9.
21. Brass LF, Vassallo RR, Belmonte E, et al. Structure and func-
tion of the human platelet thrombin receptor. J Biol Chem
1992;267:13795-8.
22. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW II. Monocyte
chemotaxis: stimulation by specific exosite region in throm-
bin. Science 1983;220:728-31.
23. Hung DT, Vu TKH, Nelken NH, Coughlin SR. Thrombin
induced events in non-platelet cells are mediated by the
unique proteolytic mechanism established for the cloned
platelet thrombin receptor. J Cell Biol 1992;116:827-32.
24. Chen LB, Buchanan JM. Mitogenic activity of blood compo-
nents; I: Thrombin and prothrombin. Proc Natl Acad Sci
USA 1975;72:131-5.
25. Walz DA, Anderson GF, Ciaglowski RE, et al. Thrombin
elicited contractile responses of aortic smooth muscle. Proc
Soc Exp Biol Med 1985;180:518-26.
26. McNamara CA, Sarembrock IJ, Gimple LW, et al. Thrombin
stimulates proliferation of cultured rat aortic smooth muscle
cells by a proteolytically activated receptor. J Clin Invest
1993;91:94-8.
27. Antonaccio MJ, Normandin D, Serafino R, Moreland S.
Effects of thrombin and thrombin activating peptides on rat
aortic vascular smooth muscle. J Pharmacol Exp Ther
1993;266:125-32.
28. Cox JST. The maturation and canalization of thrombi. Surg
Gynecol Obstet 1963;116:593-9.
29. Moser KM, Guisan M, Bartimmo EE, et al. In vivo and post-
mortem dissolution rates of pulmonary emboli and venous
thrombi in the dog. Circulation 1973;48:170-8.
30. Flanc C. An experimental study of the recanalization of arte-
rial and venous thrombi. Br Surg 1968;55:519-24.
31. Gottlob R, Mattausch M, Porschinskl K, Kramar R. The pos-
sible role of leukocytes in spontaneous and induced throm-
bolysis and some properties of leukocyte protease. Prog
Chem Fibrinol Thrombol 1978;3:391-415.
32. Gramse M, Bingenheimer C, Haverman K. Degradation of
human fibrinogen by chymotrypsin-like neutral protease
from human granulocytes. Thromb Res 1980;19:201-9.
33. Folkman J. Angiogenesis and angiogenesis inhibition: an
overview. EXS 1997;79:1-8.
34. Brown KJ, Maynes SF, Bezos A, et al. A novel in vitro assay
for human angiogenesis. Lab Invest 1996;75:539-55.
35. Yoshida S, Ono M, Shono T, et al. Involvement of inter-
leukin-8, vascular endothelial growth factor, and basic fibro-
blast growth factor in tumor necrosis factor alpha-dependent
angiogenesis. Mol Cell Biol 1997;17:4015-23.
36. Van Hinsbergh VWM, Koolwijk P, Hanemaaijer R. Role of
fibrin and plasminogen activators in repair-associated angio-
genesis: in vitro studies with human endothelial cells. EXS
1997;79:391-441.
37. Maragoudakis ME. The role of thrombin in angiogenesis. In:
Maragoudakis ME, editor. Molecular, cellular, and clinical
aspects of angiogenesis. New York: Plenum Press; 1996. p.
95-103.
Submitted Oct. 7, 1997; accepted Dec. 17, 1997.
JOURNAL OF VASCULAR SURGERY
122 See-Tho and Harris July 1998
Dr. Rajabrata Sarkar (Los Angeles, Calif.). I enjoyed
your study, and I have two questions. First, you used the
term proliferation, and you showed us wall thickening in a
number of cells. I wonder if you have done any studies of
proliferation itself to find when the thrombus actually
starts, or when the cells start dividing.
Second, in the group with the clip removed, you
showed us that there is regression of the thickening of the
vein wall, and in the arterial circulation, most regression of
wall thickening is endothelium dependent. I wonder if you
have any immunohistochemical studies on whether there
is any endothelium there after the thrombus is gone and
whether this is mediating the remodeling that you saw.
Dr. See-Tho. Your questions are good questions and, in
fact, are the significant points that we actively are pursuing at
this time. We have started some studies with bromod-
eoxyuridine labeling to determine the degree of cell prolifer-
ation. In addition to the regression, we also take our speci-
mens and use more immunohistochemical analysis for
endothelial cells and inflammatory cells.
Dr. Phillip Dobrin (Salt Lake City, Utah). I would
like to make a comment. First, I compliment you on a
nice study; I enjoyed the presentation.
I agree with your conclusions. The thrombus in
contact with the walls is a critical stimulus for cellular
proliferation. What I will describe supports your find-
ings in part.
In our laboratory, we examined deliberately occlud-
ed vein grafts in dogs and then treated them with either
balloon embolectomy or lytic therapy. Frankly, we
expected to see more intimal hyperplasia with balloon
embolectomy than with lytic therapy. Both treatments
reestablished flow. However, to our surprise, the two
techniques produced absolutely identical levels of intimal
hyperplasia in both the vein grafts and the proximal and
distal arteries where we examined. So, therefore, I agree
with you that it is the presence of the thrombus in con-
tact with the wall for a prolonged period of time that is
enough to produce the stimulus. In our case, I think it
was about 48 hours. I compliment you on that.
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